V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Ironwood Pharmaceuticals Executive Compensation (FY25)

IRWD · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Thomas McCourt
Latest say-on-pay support
=
June 16, 2026
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Ironwood Pharmaceuticals brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
Data as of October 22, 2026Latest filing (8-K): June 18, 2026
15 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Ironwood Pharmaceuticals brief$1,500Get the executive brief
Velarion Member, one year
232 figures on this page: 222 cited to the filing that reported them, 10 calculated from figures it prints. See the citations
This company is not required to report a chief executive pay ratio.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Thomas McCourt: $6,083,631 → $1,948,390 (68.0% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Ironwood Pharmaceuticals' chief executive and what were they paid?
Total compensation for Thomas McCourt, Chief Executive Officer, came to $1,948,390 in fiscal 2025. McCourt's total moved 68.0% lower from the $6,083,631 reported for fiscal 2024.
What was Ironwood Pharmaceuticals' say-on-pay result?
The say-on-pay proposal drew 95.5% of votes cast for or against in favor at the meeting held June 16, 2026 for fiscal 2025.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Thomas McCourt
Chief Executive Officer
◇◇◇—◇—◇◇
Jason Rickard
Senior Vice President, Chief Operating Officer
◇◇◇—◇—◇◇
Michael Shetzline
Senior Vice President, Chief Medical Officer, and Head of Research and Drug Development
◇◇◇—◇—◇◇
John Minardo
Senior Vice President, Chief Legal Officer and Secretary
◇—◇—◇—◇◇
Sravan Emany
Senior Vice President, Chief Financial Officer
◇———◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Thomas McCourt
Chief Executive Officer
◇—◇—◇—◇◇
Sravan Emany
Senior Vice President, Chief Financial Officer
◇—◇—◇—◇◇
Andrew Davis
Senior Vice President, Chief Business Officer
◇—◇—◇—◇◇
Michael Shetzline
Senior Vice President, Chief Medical Officer, and Head of Research and Drug Development
◇—◇—◇—◇◇
John Minardo
Senior Vice President, Chief Legal Officer and Secretary
◇—◇—◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Thomas McCourt
Chief Executive Officer
◇—◇—◇—◇◇
Sravan Emany
Former Senior Vice President, Chief Operating Officer and Chief Financial Officer
Departed during or after this year
◇—◇———◇◇
Andrew Davis
Former Senior Vice President, Chief Business Officer
Departed during or after this year
◇—◇———◇◇
Michael Shetzline
Senior Vice President, Chief Medical Officer, and Head of Research and Drug Development
◇—◇—◇—◇◇
John Minardo
Senior Vice President, Chief Legal Officer and Secretary
◇—◇—◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Thomas McCourt
Chief Executive Officer
◇—◇—◇—◇◇
Tammi Gaskins
Senior Vice President, Chief Commercial Officer
◇—◇—◇—◇◇
Gregory Martini
Senior Vice President, Chief Financial Officer
◇—◇—◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Gregory MartiniRSU◇——◇——◇
Tammi GaskinsRSU◇——◇——◇
Fiscal 2022, 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Thomas McCourtPSU◇◇——
PSU◇◇——
Option◇—◇—
RSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
Tammi GaskinsPSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
Gregory MartiniPSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Gregory Martini
Senior Vice President, Chief Financial Officer · Severance agreement
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇
Non-solicit period◇
Clawback◇
Tammi Gaskins
Senior Vice President, Chief Commercial Officer · Severance agreement
Severance multiple◇
Change-in-control multiple◇
Equity acceleration on change in control◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇
Non-solicit period◇
Thomas McCourt
Chief Executive Officer · Severance agreement
Severance multiple◇
Change-in-control multiple◇
Equity acceleration on change in control◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇
Non-solicit period◇
Clawback◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Julie McHugh
Board chair
◇◇————◇
Catherine Moukheibir
◇◇————◇
Andrew Dreyfus
◇◇————◇
Jon Duane
◇◇————◇
Jay Shepard
◇◇————◇
Mark Currie
◇◇————◇
Marla Kessler
◇◇————◇
Alexander Denner
◇◇————◇
Thomas McCourt served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Rsas.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Tax and Accounting Considerations symbol not shown

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 16, 2026=◇◇◇
2024June 10, 2025=◇◇◇
2023June 18, 2024=◇◇◇
2022June 20, 2023=◇◇◇
2021June 1, 2022=◇◇◇
2020June 2, 2021=◇◇◇
2019June 3, 2020=◇◇◇
2018May 30, 2019=◇◇◇
2017May 31, 2018=◇◇◇
2016May 31, 2017=◇◇◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Thomas McCourt (Chief Executive Officer), FY2025 total compensation $1,948,390 (base salary $867,568) [exec_comp, SEC accession 0001104659-26-050325, filed 2026-04-28]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Ironwood Pharmaceuticals files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Ironwood Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Ironwood Pharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Ironwood Pharmaceuticals' disclosed peer group is defensible, who names Ironwood Pharmaceuticals back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
232 figures on this page: 222 cited to the filing that reported them, 10 calculated from figures it prints.
222 cited to the filing
10 calculated from the filing

Documents cited

  1. 0001104659-26-075730
    8 15,446,984 2. The stockholders approved, on a non-binding advisory basis, the compensation paid to the Company’s named executive officers, as disclosed in the Proxy Statement for the Annual Meeting
  2. 0001104659-26-050325
    Compensation Tables
  3. 0001104659-25-058883
    5 17,527,704 2. The stockholders approved, on a non-binding advisory basis, the compensation paid to the Company’s named executive officers, as disclosed in the Company’s proxy statement for the Annua
  4. 0001104659-25-040309
    Compensation Tables
  5. 0001104659-24-073736
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001104659-24-051992
    Compensation Tables
  7. 0001104659-23-073747
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001104659-23-051441
    Compensation Tables
  9. 0001104659-22-068072
  10. 0001104659-21-076450
  11. 0001104659-20-070834
  12. 0001104659-19-033121
    Item 5.07 Submission of Matters to a Vote of Security Holders
  13. 0001558370-19-001005
    Employment Agreement
  14. 0001104659-18-037615
    Item 5.07 Submission of Matters to a Vote of Security Holders
  15. 0001104659-17-037226
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Ironwood Pharmaceuticals executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/IRWD (accessed 2026).
Short form: data: Velarion

The Ironwood Pharmaceuticals brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
15 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Ironwood Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy